Savant Capital LLC Has $814,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Savant Capital LLC trimmed its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 29.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,995 shares of the medical research company's stock after selling 4,542 shares during the period. Savant Capital LLC's holdings in Edwards Lifesciences were worth $814,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences during the fourth quarter worth $30,000. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth about $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after acquiring an additional 308 shares during the period. Finally, Roble Belko & Company Inc acquired a new position in Edwards Lifesciences in the fourth quarter worth about $46,000. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on EW. Evercore ISI decreased their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Truist Financial reissued a "hold" rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Barclays boosted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $79.95.

Edwards Lifesciences Trading Down 1.2 %

Shares of Edwards Lifesciences stock traded down $0.95 during trading on Wednesday, hitting $74.73. 2,253,553 shares of the company were exchanged, compared to its average volume of 4,488,136. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm's fifty day moving average price is $72.82 and its 200 day moving average price is $69.79. The firm has a market capitalization of $44.07 billion, a P/E ratio of 10.72, a price-to-earnings-growth ratio of 4.92 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now directly owns 60,372 shares of the company's stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 in the last ninety days. Insiders own 1.27% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.